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Abstract
Background: The antioxidant and anti-inflammatory effects of arbutin protect against a number of diseases.
Objectives: The present study evaluated the protective effect of arbutin against carbon tetrachloride (CCl4)-induced hepatotoxicity
in rats.
Methods: Sixty-three Wistar rats were divided into nine groups. Groups I and II were the normal control groups. Group III, the
hepatotoxic group, was given CCl4. Groups IV, VI, and VIII received different dosages of arbutin along with CCl4. Groups V, VII, and IX
were administered different dosages of arbutin. The albumin content, total protein, and bilirubin were assayed to determine their
serum and antioxidant levels; lipid peroxidation was assessed in the serum and liver tissue. Histological studies were carried out to
confirm the biochemical results.
Results: Treatment with CCl4 for 28 d decreased the levels of total protein and albumin and increased the level of bilirubin and
lipid peroxidation. Arbutin treatment raised the level of albumin and lowered the lipid peroxidation to normal levels. Necrosis and
fibrosis were observed in the liver tissue of CCl4-injected rats, and the administration of arbutin had a protective effect on the liver
tissue.
Conclusions: The results of this study showed that arbutin may protect the liver against CCl4-induced oxidative damage in rats.
This hepatoprotective effect might be correlated with the antioxidant and free radical scavenger effects of arbutin.
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1. Background
It is well known that the liver is intimately involved
in biochemical activities in the human body (1). This or-
gan plays a pivotal role in the metabolism and detoxifica-
tion of constituents that enter the body (2). The liver regu-
lates hemostasis (3) and appears to have the physiological
function of protecting the body from harmful drugs and
chemicals (3). Considering the high prevalence of liver dis-
ease globally (2), the pathogenesis of this disease is an im-
portant public health problem (4). Despite significant sci-
entific advancements in the field of hepatology in recent
years, the incidence of liver disease is still increasing (3).
Cell damage caused by free radicals is the leading mecha-
nism of hepatotoxicity (5).
Carbon tetrachloride (CCl4) is a common toxin used
to induce liver injury (6) in experimental studies. Hepatic
responses in rats to chronic CCl4 stimulation are superfi-
cially similar to human cirrhosis (7). The mechanism initi-
ates lipid peroxidation and protein oxidation, which leads
to liver damage (8).
In vitro and in vivo experiments have demonstrated
that select herbs protect against oxidative damage by in-
hibiting or quenching free radicals and reactive oxygen
species (ROS) (9). Pyrusbiossieriana is a species of pear
that is native to Iran. Its leaves contain high levels of ar-
butin, a glycosylated hydroquinone that inhibits tyrosi-
nase. This plant has a variety of pharmacological and ther-
apeutic properties, including anti-inflammatory, antiviral,
anti-hyperglycemic, anti-hyperlipidemic, and antioxidant
activity (10). It has been shown to scavenge free radicals
(11), be gastroprotective (12), and exhibit alpha-glycosidase
and alpha-amylase inhibitory activity (13). Previous studies
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have revealed that plants containing polyphenols demon-
strate clear anti-hepatotoxic properties (14).
2. Objectives
The present study investigated the antioxidant poten-
tial of arbutin on biochemical factors, CCl4-mediated ox-
idative stress, and hepatocyte dysfunction in CCl4-induced
liver damage in rats.
3. Methods
3.1. Animals
For this study, 63 apparently healthy male Wistar rats
(150 - 200 g) were obtained from the animal facility at Babol
University of Medical Sciences in the city of Babol in Iran.
They were housed in wire-floored cages under standard
laboratory conditions with a 12-hour light/12-hour dark cy-
cle at 25± 2°C and had access to a standard rat chow diet
and water ad libitum. The experimental protocols were ap-
proved by the research committee of Babol University of
Medical Sciences. This study was carried out in accordance
with the guidelines of the institutional animal ethics com-
mittee.
3.2. Drugs and Chemicals
CCl4 was purchased from Merck (Germany). Thiobar-
bituric acid (TBA) and 2, 4, 6-tripyridyl-s-triazine (TPTZ)
were obtained from Sigma Aldrich (US). Biochemical fac-
tors and enzymes were determined using standard spec-
trophotometry with high accuracy assay kits obtained
from ZiestChem (Tehran, Iran). Arbutin powder with a pu-
rity higher than 98% was procured from Sigma Aldrich
(Germany). All chemicals and solvents were of the high-
est available commercial grade and were purchased from
standard commercial suppliers.
3.3. Experimental Protocol
The animals were acclimated to the laboratory envi-
ronment for a period of 10 days prior to the commence-
ment of the experiment. During this stabilization time,
they had access to food and water ad libitum. The accli-
mated rats were randomly divided into nine groups of
seven each and were treated for 28 days as follows:
• Groups I and II were the controls, and they received
the vehicle of normal saline (1 mL oral and 0.5 mL intraperi-
toneally (IP), respectively).
• Group III was given CCl4 (1 mL/kg IP) twice weekly for
28 days.
• Groups IV, VI, and VIII received arbutin (50 mg/kg IP;
75 mg/kg IP; and 250 mg/kg orally, respectively) admin-
istered simultaneously with the CCl4 (1 mL/kg IP) twice
weekly for 28 dys.
• Groups V, VII, and IX were administrated arbutin (50
mg/kg IP; 75 mg/kg IP; and 250 mg/kg orally, respectively)
for 28 days.
In previous studies, the dosage and timing of CCl4
has been demonstrated to successfully and consistently in-
duce hepatotoxicity (15, 16). The animals were anesthetized
with chloroform 24 hours after the last injection and then
sacrificed. Blood samples were taken from the rats’ axillary
artery, and the liver was removed. Serum was separated
from the blood by centrifugation for measurement of bio-
chemical factors, thiobarbituric acid-reacting substances
(TBARS), and ferric reducing antioxidant power (FRAP). The
liver samples and serum were isolated and stored at -80°C
for later analysis. The dose and duration of the injections
were chosen according to the results of previous studies.
3.4. Total Antioxidant Activity
Total antioxidant activity was determined by FRAP
assay. This method is based on the reduction of ferric-
tripyridyltriazine [Fe (III)-TPTZ] complex to ferrous-
tripyridyltriazine [Fe (II)-TPTZ] in the presence of an-
tioxidants. The FRAP reagent was prepared using 10
mmol/L TPTZ solution in 40 mmol/L HCl plus FeCl3 (20
mmol/L) and an acetate buffer (0.3 mol/L; pH: 3.6) at a 1: 1:
10 ratio, respectively. The freshly prepared FRAP reagent
was warmed to 37°C for 5 minutes. The serum sample
or standard (50 µL) was then mixed with 1.5 mL of the
FRAP reagent and incubated at 37°C for 10 minutes. The
absorbance of the colored Fe (II)-TPTZ was measured at 593
nm and compared with a blank. A FeSO4 solution was used
as the standard at various concentrations (125, 250, 500,
and 1000µM) (17).
3.5. Evaluation of Serum TBARS
The TBARS assay was used to measure serum lipid per-
oxidation to estimate the malondialdehyde (MDA) concen-
tration. The working TBARS solution contained 0.375% TBA
and 15% trichloroacetic acid (TCA; Sigma Aldrich) in 0.25 N
HCl. The TCA/TBA/HCl reagent was freshly prepared, and 2
mL of this solution was mixed with 0.5 mL of the serum
or the standard. The solution was then heated for 15 min-
utes in a boiling water bath. After cooling, the absorbance
was measured at 532 nm against a blank that contained all
the reagents minus the serum. Different concentrations of
MDA (0, 9, 18, and 30µM) were used as the standards (18).
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3.6. Histological Analysis
Small slices of the liver were excised from the anterior
part of the left lobe, fixed immediately in a 10% buffered
formalin phosphate solution, embedded in paraffin, and
sectioned at 5 µm. The serial sections were stained with
trichrome for histomorphometric study and hematoxylin-
eosin (H&E) for a blind histological assessment that in-
cluded an evaluation for portal inflammation, hepatocel-
lular necrosis, and hepatocytes hyperplasia. Examination
of the surface areas of the hepatocytes was done using a
high-resolution (250x) Olympus CKX41 microscope (Olym-
pus; Tokyo) with a photographic facility. At least 100 hepa-
tocytes were measured from each zone of every liver slice.
For each, the cytoplasmic and nuclear areas were calcu-
lated using Motic software; other parameters, such as the
total cell surface and nuclear/cytoplasm ratio, were ob-
tained from the data using the statistical package for the
social sciences (SPSS) software.
3.7. Statistical Analysis
The statistical analysis was carried out using SPSS soft-
ware, version 15.0 (SPSS, Inc., Chicago, IL, US). The difference
between groups was determined by a one-way analysis of
variance (ANOVA) with post-hoc Tukey testing. A level of P
< 0.05 was defined as statistically significant.
4. Results
4.1. Biochemical
Figure 1 shows the liver function indices for albumin,
total protein, and bilirubin concentrations in the serum
of rats with CCl4-induced liver damage after the daily ad-
ministration of arbutin for 28 d. The total protein (TP) de-
creased significantly for the groups that received CCl4 com-
pared with the normal group (P = 0.001). TP decreased in
Groups V, VII, and IX (P < 0.05). The serum albumin con-
centrations of the groups injected with CCl4 were signifi-
cantly lower than those of the control groups (P < 0.001),
and there was a significant increase in this factor in Groups
V, VII, and IX (P < 0.05). Groups IV, VI, and VIII demonstrated
a significant increase in the serum bilirubin (P < 0.001).
The bilirubin levels in the CCl4-induced groups increased
significantly over the normal group (P < 0.001). The biliru-
bin levels of Groups V, VII, and IX increased but were lower
in Groups IV, VI, and VIII (P < 0001).
4.2. Lipid Peroxidation
Figure 2 shows that the mean TBARS increased sig-
nificantly in the CCl4 groups compared with the normal
groups (P = 0.001). In Groups IV, VI, and VIII, there was a
significant decrease in the mean TBARS (P < 0.05), which
Figure 1. The Effects of Daily Doses of Arbutin on Serum Total Protein, Albumin, and
Total Bilirubin Levels of CCl4 -Induced Liver Damage In Rats
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Values are expressed as mean± SEM. of seven animals in each group (except groups
6 and 8 which are six) Statistical analysis ANOVA followed by Post-Hoc Tukey.
was likely due to the decrease in lipid peroxidation in the
hepatic tissue. In Group IX, orally administered arbutin
showed significant, dose-dependent hepatoprotective ac-
tivity in comparison with the results for the groups receiv-
ing 50 and 75 mg/kg IP injections (Figure 2).
Figure 2. The Effect of Arbutin and CCl4 on Lipid Peroxidation in Rat Serum and
Tissue
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The unit of lipid peroxidation is nm. Values are expressed as mean± SEM. of seven
animals in each group (except groups 6 and 8 which are six) Statistical analysis
ANOVA followed by Post-Hoc Tukey.
4.3. Antioxidant Capacity
Figure 3 shows that CCl4 injections partially increased
liver tissue antioxidant activity (FRAP), but there was no
significant difference between the toxin group and the
treated groups. A comparison of the groups that received
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different dosages of arbutin showed a decrease in the an-
tioxidant activity in the liver tissue of the group treated
with 75 mg/kg IP of arbutin over the group that was admin-
istered 50 mg/kg IP of arbutin (P = 0.017).
Figure 3. The Effect of Arbutin and CCl4 on the Antioxidant Capacity of Rat Serum
and Tissue
1000
900
800
700
600
500
400
300
200
100
0
No
rm
al 
Sa
lin
e
No
rm
al 
Sa
lin
e
CC
l4
CC
l4+
 50
 m
g/k
g A
rb
ut
in
50
 m
g/k
g A
rb
ut
in
CC
l4+
 75
 m
g/k
g A
rb
ut
in
CC
l4+
 25
0 m
g/k
g A
rb
ut
in
75
 m
g/k
g A
rb
ut
in
25
0 m
g/k
g A
rb
ut
in
Serum FRAP
Liver FRAP
The unit of antioxidant capacity is nm. Values are expressed as mean ± SEM. of
seven animals in each group (except groups 6 and 8 which are six) Statistical analysis
ANOVA followed by Post-Hoc Tukey.
4.4. Change in Body Weight
Figure 4 indicates that the body weight of all groups
decreased after CCl4 injection but reverted to near normal
in the groups that were treated with arbutin (P < 0.001).
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Figure 4. Effect of Arbutin and CCl4 on Rat Body Weight Changes
4.5. Histological Results
Histopathological studies of the liver in both the con-
trol and arbutin-treated animals were normal. Addition-
ally, we observed significant liver destruction, inflamma-
tion, fibrosis, and necrosis after CCl4 administration. In
rats that received CCl4+arbutin (50 IP), the hepatocyte nu-
cleus was dense, and fibrosis was also noted. In rats that
were administered CCl4+arbutin (75 IP), we observed a very
similar result that was a little bit milder. Group IX received
CCl4+arbutin (250 orally), and its histology was the same
as that of the normal groups.
The quantitative parameters of the hepatocyte area, cy-
toplasmic area, nuclear area, and nuclear/cytoplasmic ra-
tio are given in Table 1 and Figure 5.
4.6. Changes in the Total Area of Hepatocytes
The mean hepatocyte area was significantly higher in
CCl4-injected rats (P = 0.003) and lower in the arbutin (IP
50 mg/kg) treated group than in that of rats in the normal
group. In addition, we saw significant decreases in groups
that received CCl4+different doses of arbutin in compari-
son with the toxic group (P < 0.001).
4.7. Changes in the Nuclear Area
The measurement of the nuclear areas revealed a sig-
nificant increase in the toxic group (P < 0.001). Further-
more, there was a significant decrease in the groups of dif-
ferent doses of arbutin compared with the CCl4 group (P <
0.001).
4.8. Changes in the Cytoplasmic Area
The mean cytoplasmic area in the toxic group was sig-
nificantly higher than the level found in normal rats (P <
0.001).
4.9. Changes in the Nuclear/Cytoplasm Ratio
The mean nuclear/cytoplasm ratio in rats treated with
arbutin was significantly lower than that of the normal
group (P < 0.001).
5. Discussion
The present study showed that the dosage of CCl4 (1
mL/kg) significantly changed the TP, bilirubin, and albu-
min levels, which is indicative of impaired liver function;
these parameters are sensitive indicators of liver dam-
age (19, 20). It is generally accepted that liver damage
and hepatotoxicity induced by CCl4 is the best model for
screening the protective and antioxidant activity of plant
extracts/drugs experimentally (21-23). Numerous studies
have indicated that hepatic damage induced by CCl4 is
caused by the accumulation of CCl4 in hepatic parenchy-
mal cells that are metabolically activated by cytochrome
P-450 dependent monoxygenases to form metabolites of
4 Jundishapur J Nat Pharm Prod. 2016; 11(3):e33392.
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Table 1. Quantitative Parameters of the Hepatocyte Area, Cytoplasmic Area, Nuclear Areas, and Nucleolar/Cytoplasmic Ratio in Hepatocytes in the Control, CCl4 -Injected, and
Arbutin-Treated Groupsa
Hepatocyte,µm2 Cytoplasmic Area,µm2 Nucleolar Area Nucleular v/Cytoplasmic Ratio
Oral normal saline 237.53± 1.38 143.10± 1.35 94.43± 0.51 0.39± 0.002
IP normal saline 241.78± 1.68 135.48± 1.62 106.29± 0.87 0.43± 0.009
IP CCL4 255.41± 2.90b 149.93± 3.83c 105.47± 3.31b 0.40± 0.006b
IP CCL4+IP arbutin 50 236.31± 2.14c 138.07± 2.05d 98.23± 0.77c , e 0.39± 0.003c , e
IP Arbutin 50 231.40± 1.78b , c 138.02± 1.68d 93.37± 0.58c , d 0.39± 0.002c
IP CCL4+IP arbutin 75 241.00± 2.27d 146.73± 2.03b 94.26± 0.85c , d 0.38± 0.003c , e
IP arbutin 75 235.42± 1.91c , d 142.80± 1.84e 92.62± 0.62c , d 0.38± 0.002c
IP CCL4+oral arbutin 250 253.15± 2.58b 159.21± 2.28b , e 93.94± 0.68d 0.36± 0.003c , d
Oral arbutin 250 239.67± 2.34d 144.48± 3.83b 95.19± 3.39b , d 0.39± 0.011b , e
aValues are expressed as the mean± SEM of seven animals in each group (except in Groups VI and VIII, which included six animals) statistical analysis ANOVA followed
by Post-Hoc Tukey.
bP≤ 0.001 vs. the normal group.
cP < 0.05 vs. the normal group.
dP≤ 0.001 vs. the CCl4 group.
eP < 0.05 vs. the CCl4 group.
trichloromethyl free radicals (CCl3•) that cause lipid perox-
idation and hepatocellular membrane damage. This pro-
cess is followed by the release of growth factors, inflamma-
tory mediators, and prostaglandins from activated hepatic
macrophages that potentiate CCl4-induced hepatic injury
(15, 24, 25).
The ability of a hepatoprotective drug to alleviate the
injurious effects or conserve normal hepatic physiologi-
cal mechanisms affected by a hepatotoxin is the index of
its protective effects (26). The present study examined the
hepatoprotective and antioxidant role of arbutin on CCl4-
induced liver damage in rats.
Free radicals affect the pathological manifestation and
inflammatory response and can contribute to liver dam-
age (27). The body has an effective mechanism to inhibit
and neutralize free radical-induced damage using a set
of endogenous antioxidant enzymes. When the balance
between ROS production and antioxidant defense is de-
stroyed, oxidative stress results, which deregulates cellu-
lar function and leads to various pathological conditions
(25). Antioxidants can suppress free radical production,
which makes them crucial for protection of the liver from
chemical-induced damage through their stabilization of
the antioxidant systems in the cell (28).
Prior studies have demonstrated the antioxidative and
free radical scavenging properties of arbutin (29, 30). How-
ever, no studies thus far have reported on the in vitro cy-
totoxic activity of this natural compound for normal liver
cells to demonstrate its ability to prevent acute tissue dam-
age (12). The low toxicity of arbutin is in accordance with
previous in vitro studies on human melanocytes that were
exposed to arbutin (31).
One important and sensitive test employed in the di-
agnosis of hepatic disease is the serum bilirubin concen-
tration, which provides essential information on how well
the liver is functioning (32). Bilirubin is a product of the
chemical breakdown of hemoglobin that increases water
solubility in hepatocytes in conjugation with glucuronic
acid (33). The present study showed a significant increase
in the bilirubin levels of CCl4-injected rats, which is in ac-
cordance with the findings of previous studies (19, 34, 35).
This hyper-bilirubinemia may be caused by the inhibition
of the conjugation reaction and also the release of uncon-
jugated bilirubin from injured and dead hepatocytes (33).
Serum bilirubin decreased to normal levels after treat-
ment with arbutin, which demonstrates the effectiveness
of arbutin in the maintenance of the normal functional
status of the liver. Albumin is a key component of serum
proteins. It is synthesized in the liver and is one factor used
to monitor liver function (36). Studies have shown that
liver toxicity decreases serum albumin levels (37). The re-
sults of the present study are in agreement with this find-
ing and demonstrate the decreased functional ability of
CCl4-injected rat livers (33). Decreased serum TP and albu-
min levels have been reported in CCl4-administered rats
(38). In contrast, a significant increase in the serum TP and
albumin levels was observed in the groups that received
both arbutin and CCl4. Stabilization of the serum protein
levels by treatment with arbutin is a clear indication of an
improvement in the functional status of the liver cells.
Increasing evidence supports the hypothesis that CCl4-
induced liver damage may be a consequence of oxidative
Jundishapur J Nat Pharm Prod. 2016; 11(3):e33392. 5
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Figure 5. Trichrome-Stained Sections
Typical images were chosen from the different experimental groups (original magnification: X40); (A, B), The control group demonstrated bright and marked nucleoli; (C),
The CCl4 -injected rats had multiple and extensive areas of portal inflammation and hepatocellular necrosis and a moderate increase in inflammatory cell infiltration and also
severe fibrosis; (D), CCl4 and 50 mg/kg IP arbutin: minimal hepatocellular inflammatory cell infiltration and mild portal inflammation and fibrosis; (E), 50 mg/kg IP arbutin
was associated with a normal lobular architecture and cell structure; (F), CCl4 and 75 mg/kg IP arbutin produced moderate inflammation and fibrosis; (G), 75 mg/kg IP arbutin
was near to normalcy; (H), CCl4 and 250 mg/kg oral arbutin. The liver showed a normal histological profile; (I), 250 mg/kg oral arbutin: the liver showed a normal histological
profile.
stress (39, 40). The results of this study are in agreement
with this hypothesis. Previous studies have demonstrated
the antioxidant activities of arbutin (41). Lipid peroxida-
tion has been involved in the pathogenesis of hepatic in-
jury by free radical derivatives of CCl4 and is responsible
for cell membrane damage and the subsequent release
of marker enzymes of hepatotoxicity (22, 40, 42). In the
present study, significantly elevated levels of TBARS, the
product of membrane lipid peroxidation observed in CCl4-
administered rats, indicated hepatic damage. In contrast,
treatment with arbutin prevents lipid peroxidation and
may be attributed to its radical scavenging antioxidant
constituents (43).
The observed histopathologic changes indicating liver
damage after CCl4 administration confirmed the results of
the biochemical studies. It was previously reported that
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CCl4 causes liver necrosis, steatosis, degeneration of hep-
atocytes (44), and cirrhosis (7, 45). CCl4 was also found to
precipitate apoptosis in the liver (46). The histopathologic
findings in the liver caused by CCl4 administration in the
present study are in agreement with the results of previous
studies. Pretreatment with arbutin significantly improved
the structure of hepatic cells.
These results suggest that arbutin is effective at revers-
ing the hepatotoxicity caused by CCl4. Morphometric stud-
ies have confirmed these observations. The increased cyto-
plasmic area in the toxic group may be the result of smooth
endoplasmic reticulum proliferation in hepatocytes (47,
48). Nuclei are responsible for RNA production and the
consequent cytoplasmic protein synthesis (49, 50). The an-
tioxidant effects of arbutin may therefore contribute to the
partial or total alleviation of such damage. The histological
and biochemical results agree.
5.1. Conclusion
This study showed that arbutin provides protection
from the effects of CCl4-induced hepatocellular damage,
which is likely due to its ability to scavenge free radicals.
Liver cells treated with arbutin suppressed the changes
that were induced by CCl4. These findings suggest that ar-
butin can be used as an antioxidant to protect the liver
from the oxidative damage induced by toxic chemicals.
More studies are needed to examine the exact mechanisms
operating in arbutin and to evaluate its therapeutic effect
on hepatic injury induced by chemicals.
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